By Daniella Parra
Ashvattha Therapeutics has appointed Robert J. Dempsey as Interim CEO, tapping an ophthalmology veteran with a track record of transformative deals and launches, they said.
Recently, Ashvattha announced positive Phase 2 results for migaldendranib, a novel subcutaneous nanomedicine showing a significant reduction in intravitreal injections, with a 83% reduction in nAMD patients and a 78.6% reduction in DME patients —potentially eliminating the frequent eye injections that have been the standard of care, the company said.
“The FDA alignment on our Phase 2b/3 protocol, combined with the encouraging Phase 2 data, provides a strong foundation as we advance migaldendranib through pivotal development,” Robert J. Dempsey, Interim CEO, said. “Having led major transactions in ophthalmology, I see significant potential for this differentiated subcutaneous therapy that could meaningfully reduce treatment burden for patients with DME and nAMD.”
Updated Preliminary Agenda: 5th Palm Beach CorpGov Forum Nov 5-6
Never Miss our Weekly Highlights HERE
